Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship between LDLR genotype and the plasma levels of PCSK9, LDL-C, and lipoprotein (a) (Lp(a)) in a large cohort of genetically defined FH heterozygotes (HeFH).
|
26371983 |
2015 |
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the associations of lipoprotein (a) [Lp(a)] with the FH phenotype, genotype and roles of Lp(a) in determining CAD risk among patients with and without FH.
|
28351002 |
2017 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia.
|
7607414 |
1995 |
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of the present study is to compare the predictive value of an LPA variant, rs10455872, as well as Lp(a) concentration on the prevalence of CVD and on the age of the first CVD event in a cohort of genetically confirmed heterozygous patients with familial hypercholesterolemia (FH).
|
31103339 |
2019 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
|
28502508 |
2018 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear.
|
26340131 |
2015 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.
|
29480541 |
2018 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia.
|
1836489 |
1991 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An investigation of the influence of selected factors on the clinical expression of the FH Afrikaner-1 mutation in this family indicated that it was especially the elevated apolipoprotein (a) levels, in addition to low levels of high density lipoprotein cholesterol and raised triglyceride and apolipoprotein B levels, that were associated with a greater risk of developing CHD.
|
8370148 |
1993 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirmed that the MFHS is a strong predictor of prevalent CVD in FH and that the addition of lipoprotein(a) offers a minor improvement in the discrimination of the score.
|
28801029 |
2018 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein (a) [apo(a)] phenotype was determined in 112 of FH and non-FH subjects.
|
8548413 |
1996 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia.
|
31436336 |
2019 |
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 and 3 clinical trials in patients with moderate and severe hypercholesterolemia (including FH) show that this approach is safe and highly efficacious to lower LDL-C and lipoprotein(a).
|
25248569 |
2014 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).
|
29096862 |
2017 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of lipoprotein (a) in children with familial hypercholesterolemia.
|
8197753 |
1994 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
|
26632531 |
2016 |
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).
|
30846097 |
2019 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
|
27594539 |
2016 |
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Until last year, only the LDLR and LPA genes were appreciated as loci within which clinically relevant CNVs contributed to familial hypercholesterolemia and variation in Lp(a) levels, respectively.
|
30664016 |
2019 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Total cholesterol and lipoprotein (a) were increased in FH children compared to controls (282.3+/-8.8 mg/dl vs. 163.8+/-4.6 mg/dl and 11.0[4.6, 30.7]mg/dl vs. 5.24[2.63, 11.0]mg/dl median [IQR] respectively; p<0.001 for both).
|
19004443 |
2009 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study's aim was to determine whether biochemical risk factors such as lipoprotein(a), fibrinogen, homocysteine, and insulin, as well as low-density lipoprotein (LDL) particle size, were predictive of carotid intimamedia thickness (IMT), an early marker of atherosclerosis, in subjects with familial hypercholesterolemia (FH).
|
10235090 |
1999 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic traits for familial hypercholesterolemia and high lipoprotein(a) concentrations apparently co-exist and are associated with a higher ASVCD risk than each alone.
|
31393421 |
2019 |
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent literature involving CNVs and dyslipidemias has focused mainly on rare CNVs causing familial hypercholesterolemia, and a common CNV polymorphism as the major determinant of lipoprotein(a) plasma concentrations.
|
29303791 |
2018 |
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low-density lipoprotein cholesterol (LDL-C) level and lipoprotein(a) [Lp(a)] ≥ 50 mg/dL predict atherosclerotic cardiovascular disease (ASCVD) risk in adults with familial hypercholesterolemia (FH), but their role for children with FH is less clear.
|
30150142 |
2019 |
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phenotypic diversity of familial hypercholesterolemia (FH) and lipoprotein(a) hyperlipidemia (Lp(a)-HLP), as defined risks for coronary artery disease with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revisiting of the current diagnostic and screening criteria as well as therapeutic recommendations established for FH or isolated Lp(a)-HLP, since there is no clear guidance for patient stratification and disease management for combined cases.
|
20129380 |
2009 |